A:

Biotech giant Amgen Inc (AMGN) bills itself as one of the first biotechnology firms. It was founded in 1980 and has grown into a firm with 20,000 employees, a market capitalization of nearly $100 billion, and approximately $20 billion in annual sales. Below is an overview of its main rivals.

Product Rivals

Any pharmaceutical or biotech firm is technically a rival to Amgen, though there is a smaller subset of rivals that sell similar drugs to Amgen. For instance, Johnson & Johnson (JNJ) sells Procrit, which is a competitor to Aranesp and Amgen’s stable of anemia treatments. Teva Pharmaceutical (TEVA) also sells an increasing array of biosimilar drugs to Aranesp  Amgen’s Enbrel helps treat arthritis, which competes with AbbVie’s (ABBV) popular Humira drug. Celgene (CELG) sells Revlimid to treat myeloma and Amgen is in the process of getting into the field with the acquisition of Onyx and its Kyprolis drug, also for the treatment of myeloma.      

Biotech Competition

In general, Amgen competes with other large biotech firms. Biogen Idec (BIIB) sells a number of drugs to help treat multiple sclerosis and is seeing success with the launch of a couple of drugs to treat hemophilia. Celgene sells drugs that help treat cancer and immune-inflammatory diseases. Gilead Sciences (GILD) offers a number of drugs that help patients suffering from HIV and recently released Solvadi, which has had great success in helping patients with hepatitis C infections.

The Bottom Line

A number of firms continue to muscle into Amgen’s core businesses of treating anemia, arthritis, and myeloma. Generic versions will also continue to be introduced as Amgen’s drug patents expire over time. Most investment bankers and analysts, however, still project Amgen will remain profitable over time. 

At the time of writing, Ryan C. Fuhrmann is long shares of Amgen and Gilead but did not own shares in any of the other companies mentioned in this article.

RELATED FAQS
  1. What does it mean that an investor faces binary outcomes when investing in drug companies?

    Learn why investments in biotech and drug companies can result in what are called binary outcomes, and understand why these ... Read Answer >>
  2. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  3. Who are Gilead Sciences' (GILD) main competitors?

    Learn about the pharmaceutical company Gilead Sciences and its main competitors. Explore the company's role in creating HIV-preventing ... Read Answer >>
  4. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  5. What are the differences between brand name drugs and generic drugs?

    Discover the process by which brand name drugs lose their patent, allowing generics to be manufactured, as well as the differences ... Read Answer >>
  6. What factors make the drug sector good for value investing?

    Discover what makes the drugs sector good for value investing. The perfect ingredient for value investors is to find undervalued ... Read Answer >>
Related Articles
  1. Investing

    Amgen Earnings Preview: 5 Questions to Ask (AMGN)

    In the biotechnology sector, few companies are more synonymous with innovation than Amgen (NASDAQ: AMGN). Throughout the 1980s and 1990s, Amgen was a model drug development company, rewarding ...
  2. Investing

    5 Things Amgen's Management Wants You to Know (AMGN)

    With its share price already having tripled over the trailing four-year period, Amgen (NASDAQ: AMGN) delivered more solid numbers when it reported first-quarter results on April 21. Quarterly ...
  3. Insights

    Amgen’s Kyprolis Fails in Trial (AMGN)

    The failure in a comparative study has raised doubts about Amgen’s $10.4 billion takeover of the drug.
  4. Investing

    Amgen Dazzles With a Duo of Fresh Data (AMGN)

    Sometimes it appears as if a biotech stock can do no wrong, and for shareholders of biotech behemoth Amgen (NASDAQ: AMGN), things must certainly feel that way at the moment. After its share ...
  5. Investing

    How Amgen Makes Billions On Just A Few Drugs

    Amgen produces relatively few drugs, but that's doesn't mean it's any less essential or profitable. Here's a look at the $120B company.
  6. Investing

    Amgen Q4 Earnings Beat Street Forecasts

    Amgen's 4Q earnings and revenue beat analyst projections.
  7. Investing

    A Forecast for Amgen Trends in 2017

    Amgen had a rough 2016, but the company's pipeline of new products could drive recovery in 2017.
  8. Investing

    Amgen's Dividend Could Double in 5 Years (AMGN)

    Amgen's (NASDAQ: AMGN) dividend yield of 1.9% may not look very enticing to investors looking for income today. But a close look at Amgen stock reveals that where the biotechnology company lacks ...
  9. Insights

    Long Wait for Biosimilar Amjevita (AMGN)

    While Amgen’s Humira biosimilar called Amjevita has been approved by the FDA, it will be a very long wait for real commercial benefits.
  10. Insights

    Amgen's Biosimilar Gets FDA Approval (AMGN, ABBV)

    The company’s first biosimilar, Amjevita, is now approved for seven common inflammatory ailments and may encroach on AbbVie's $8.4 billion monopoly.
RELATED TERMS
  1. Abbreviated New Drug Submission (ANDS)

    A written request to Health Canada to obtain marketing approval ...
  2. Orange Book

    A list of drugs that the U.S. Food and Drug Administration has ...
  3. Orphan Drug

    A drug or biological product that treats a rare condition or ...
  4. New Drug Application (NDA)

    The final step formally taken by a drug sponsor, wherein it applies ...
  5. Food And Drug Administration - FDA

    A government agency established in 1906 with the passage of the ...
  6. Bioequivalence

    A similarity between two drugs meaning that they both have the ...
Hot Definitions
  1. Stop Order

    A stop order is an order to buy or sell a security when its price increases past a particular point in order to limit losses ...
  2. Inflation

    The rate at which the general level of prices for goods and services is rising and, consequently, the purchasing power of ...
  3. Candlestick

    A chart that displays the high, low, opening and closing prices for a security for a single day. The wide part of the candlestick ...
  4. Indicator

    Indicators are statistics used to measure current conditions as well as to forecast financial or economic trends.
  5. Liability

    Liabilities are defined as a company's legal debts or obligations that arise during the course of business operations.
  6. Security

    A security is a fungible, negotiable financial instrument that represents some type of financial value, usually in the form ...
Trading Center